Literature DB >> 15878965

Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor.

Ryuji Kouyama1, Takayoshi Suganami, Junko Nishida, Miyako Tanaka, Takuya Toyoda, Minako Kiso, Tsuyoshi Chiwata, Yoshihiro Miyamoto, Yasunao Yoshimasa, Akiyoshi Fukamizu, Masatsugu Horiuchi, Yukio Hirata, Yoshihiro Ogawa.   

Abstract

Given that angiotensin II (AII) type 1 and 2 receptors (Agtr1 and Agtr2) are expressed in adipose tissue, AII may act directly on adipose tissue. However, regardless of whether AII directly modulates adipose tissue growth and metabolism in vivo and, if so, whether it is mediated via Agtr1 are still matters of debate. To understand the functional role of Agtr1 in adipose tissue growth and metabolism in vivo, we examined the metabolic phenotypes of mice lacking Agtr1a (Agtr1a-/- mice) during a high-fat diet. The Agtr1a-/- mice exhibited the attenuation of diet-induced body weight gain and adiposity, and insulin resistance relative to wild-type littermates (Agtr1a+/+ mice). They also showed increased energy expenditure accompanied by sympathetic activation, as revealed by increased rectal temperature and oxygen consumption, increased expression of uncoupling protein-1 mRNA in brown adipose tissue, and increased urinary catecholamine excretion. The heterozygous Agtr1a-deficient mice (Agtr1a+/- mice) also exhibited metabolic phenotypes similar to those of Agtr1a-/- mice. Using mouse embryonic fibroblasts derived from Agtr1a+/+ and Agtr1a-/- mice, we found no significant difference between genotypes in the ability to differentiate into lipid-laden mature adipocytes. In primary cultures of mouse mature adipocytes, AII increased the expression of mRNAs for some adipocytokines, which was abolished by pharmacological blockade of Agtr1. This study demonstrates that Agtr1a-/- mice exhibit attenuation of diet-induced weight gain and adiposity through increased energy expenditure. The data also suggest that AII does not affect directly adipocyte differentiation, but can modulate adipocytokine production via Agtr1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878965     DOI: 10.1210/en.2005-0003

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  66 in total

1.  The platform for adipose tissue expansion during positive energy balance.

Authors:  Jonathan Krakoff
Journal:  J Clin Endocrinol Metab       Date:  2012-02       Impact factor: 5.958

2.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

Review 3.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.

Authors:  X Rong; Y Li; K Ebihara; M Zhao; T Kusakabe; T Tomita; M Murray; K Nakao
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes.

Authors:  Jan Machal; Jan Novak; Renata Hezova; Filip Zlamal; Anna Vasku; Ondrej Slaby; Julie Bienertova-Vasku
Journal:  Genes Nutr       Date:  2015-08-26       Impact factor: 5.523

6.  The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance.

Authors:  Justin L Grobe; Connie L Grobe; Terry G Beltz; Scott G Westphal; Donald A Morgan; Di Xu; Willem J de Lange; Huiping Li; Koji Sakai; Daniel R Thedens; Lisa A Cassis; Kamal Rahmouni; Allyn L Mark; Alan Kim Johnson; Curt D Sigmund
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

Review 7.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

8.  Angiotensin AT1 receptor antagonism by losartan stimulates adipocyte browning via induction of apelin.

Authors:  Dong Young Kim; Mi Jin Choi; Tae Kyung Ko; Na Hyun Lee; Ok-Hee Kim; Hyae Gyeong Cheon
Journal:  J Biol Chem       Date:  2020-08-24       Impact factor: 5.157

Review 9.  Adipokines and blood pressure control.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Lisa Cassis
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

Review 10.  Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension.

Authors:  Nicole K Littlejohn; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.